围产期HIV-1感染儿童持续病毒学抑制≥5年时外周血HIV-1 DNA与可诱导HIV-1 RNA储存库的临床相关性
加拿大EPIC4前瞻性多中心队列研究纳入228名围产期HIV-1感染儿童,其中69名达到持续病毒学抑制≥5年。HIV-1 DNA、可诱导无细胞HIV-1 RNA和信号/ cutoff比值(S/CO)与有效联合抗逆转录病毒治疗(cART)启动年龄及达到持续病毒学抑制的年龄直接相关,与接受有效cART及持续病毒学抑制的生命比例呈负相关。可诱导无细胞HIV-1 RNA与HIV-1 DNA相关,尤其在无病毒学突发的儿童中。标准商业HIV血清学可能作为外周血储存库大小的实用间接指标。
要点
- 早启动cART和早达到持续病毒学抑制与更小的HIV-1储存库相关。
- 可诱导无细胞HIV-1 RNA与HIV-1 DNA相关,在无病毒学突发者中更明显。
- 标准HIV血清学S/CO与HIV-1 DNA相关,或可间接评估储存库大小。
核心结论
- 围产期HIV-1感染儿童中,较早启动有效cART和较早达到持续病毒学抑制与较小的外周血HIV-1储存库相关。
- 标准商业HIV血清学可能作为外周血储存库大小的实用间接指标。
研究设计与样本
- EPIC4研究为前瞻性、多中心加拿大队列研究,纳入228名围产期HIV-1感染儿童,其中69名达到持续病毒学抑制≥5年。
- 通过外周血单核细胞HIV-1 DNA和CD4+ T细胞经prostratin类似物刺激试验检测可诱导无细胞HIV-1 RNA来评估储存库,并用信号/ cutoff比值(S/CO)量化HIV血清学。
主要发现
- HIV-1 DNA、可诱导无细胞HIV-1 RNA和S/CO与有效cART启动年龄直接相关(分别为P < .001、P = .036、P < .001)。
- HIV-1 DNA、可诱导无细胞HIV-1 RNA和S/CO与达到持续病毒学抑制的年龄直接相关(分别为P = .002、P = .038、P < .001)。
- HIV-1 DNA、可诱导无细胞HIV-1 RNA和S/CO与接受有效cART的生命比例呈负相关(分别为P < .001、P = .01、P < .001)。
- HIV-1 DNA、可诱导无细胞HIV-1 RNA和S/CO与持续病毒学抑制的生命比例呈负相关(分别为P < .001、P = .079、P < .001)。
- 可诱导无细胞HIV-1 RNA与HIV-1 DNA相关,在无病毒学突发且首个cART方案启动于6月龄前(rho = 0.74;P = .037)或之后(rho = 0.87;P < .001)的持续病毒学抑制儿童中尤为明显;S/CO与HIV-1 DNA相关(P = .003),与可诱导无细胞HIV-1 RNA相关性较弱(P = .09)。
临床怎么用
- 对于围产期HIV-1感染儿童,早启动cART和早达到持续病毒学抑制可能有助于限制HIV-1储存库大小。
- 标准商业HIV血清学S/CO可作为外周血储存库大小的初始间接评估工具。
- prostratin类似物刺激试验需血量较低,可能适用于儿童可诱导HIV-1储存库的评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Early Pediatric Initiation Canada Child Cure Cohort (EPIC4) study is a prospective, multicenter, Canadian cohort study investigating human immunodeficiency virus-1 (HIV-1) reservoirs, chronic inflammation, and immune responses in children with perinatally acquired HIV-1 infection. The focus of this report is HIV-1 reservoirs and correlates in the peripheral blood of children who achieved sustained virologic suppression (SVS) for ≥5 years. METHODS: HIV-1 reservoirs were determined by measuring HIV-1 DNA in peripheral blood mononuclear cells and inducible cell-free HIV-1 RNA in CD4+ T-cells by a prostratin analogue stimulation assay. HIV serology was quantified by signal-to-cutoff ratio (S/CO). RESULTS: Of 228 enrolled participants, 69 achieved SVS for ≥5 years. HIV-1 DNA, inducible cell-free HIV-1 RNA, and S/COs correlated directly with the age of effective combination antiretroviral therapy (cART) initiation (P < .001, P = .036, and P < .001, respectively) and age when SVS was achieved (P = .002, P = .038, and P < .001, respectively) and inversely with the proportion of life spent on effective cART (P < .001, P = .01, and P < .001, respectively) and proportion of life spent with SVS (P < .001, P = .079, and P < .001, respectively). Inducible cell-free HIV-1 RNA correlated with HIV-1 DNA, most particularly in children with SVS, without virologic blips, that was achieved with the first cART regimen initiated prior to 6 months of age (rho = 0.74; P = .037) or later (rho = 0.87; P < .001). S/COs correlated with HIV-1 DNA (P = .003), but less so with inducible cell-free HIV-1 RNA (P = .09). CONCLUSIONS: The prostratin analogue stimulation assay, with its lower blood volume requirement, could be a valuable method for evaluating inducible HIV-1 reservoirs in children. Standard commercial HIV serology may be a practical initial indirect measure of reservoir size in the peripheral blood of children with perinatally acquired HIV-1 infection.
引用
- Bitnun A, Ransy DG, Brophy J, et al. Clinical Correlates of Human Immunodeficiency Virus-1 (HIV-1) DNA and Inducible HIV-1 RNA Reservoirs in Peripheral Blood in Children With Perinatally Acquired HIV-1 Infection With Sustained Virologic Suppression for at Least 5 Years. Clin Infect Dis. 2020. PMID: 30919879. doi:10.1093/cid/ciz251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。